Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its human interferon gamma for injection. The therapeutic biologic product can now be used to reduce the frequency and severity of severe infections associated with chronic granulomatosis, an indication for which no other human interferon is approved in China.
Drug Profile and Sales
The drug was first approved in China to treat rheumatoid arthritis (RA) in April 1995. It generated RMB 1.72 million (USD 240,633) in sales in the country last year. This additional approval expands the therapeutic applications of human interferon gamma, positioning Fosun Pharma to address a broader range of medical needs.
Future Implications
With this new indication, Fosun Pharma further solidifies its position in the biologics market, offering a unique treatment option for patients with chronic granulomatosis. The company’s continued focus on expanding its product portfolio underscores its commitment to innovation and meeting unmet medical needs.-Fineline Info & Tech